Fig. 11From: Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer modelTime-integrated activity (TIA) of the tumor, blood, spleen, liver, kidney, and thymus for the radionuclides a 225Ac, b 212Pb, and c 211At-anti-PD-L1-BC labeled with the protein concentrations 1 mg/kg (black bar), 3 mg/kg (red bar), and 10 mg/kg (blue bar)Back to article page